Background/Aims Berberine ursodeoxycholate (HTD1801) has been shown to significantly reduce liver fat content (LFC) in an 18-week, placebo-controlled Phase 2 study in patients with metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus. The purpose of this assessment was to establish proof of concept in liver histologic improvement with HTD1801 treatment based on preclinical and clinical evidence.
Methods The efficacy of HTD1801 was evaluated in a preclinical MASH/dyslipidemia model (golden hamsters fed a high fat diet, eight/group) after six weeks of daily treatment. Additionally, in a secondary analysis of a Phase 2 clinical study, 100 patients with presumed MASH were evaluated by multiple noninvasive markers associated with MASH resolution and/or fibrosis improvement. These include magnetic resonance imaging proton density fat fraction (MRIPDFF; ≥30% LFC reduction), iron-corrected T1 (≥80 ms reduction), alanine aminotransferase (≥17 U/L reduction), weight loss (≥5% reduction), Fibrosis-4 index (shift to <1.3), and MASH resolution index (achieving ≥–0.67).
Results Preclinical findings in the MASH/dyslipidemia hamster model showed that HTD1801 significantly improved histologic fibrosis and the Nonalcoholic Fatty Liver Disease Activity Score to such a degree that improvements approximated the appearance of the normal controls. In the clinical study, 52% of HTD1801-treated patients achieved MRI response criteria compared to 24% of placebo (p<0.05). Dose-dependent improvements were observed across biomarkers, with more HTD1801-treated patients achieving response criteria associated with improvements in the histologic features of MASH.
Conclusions These findings suggest that HTD1801 has strong potential to produce histological improvements in patients with MASH.
Citations
Citations to this article as recorded by
Molecular mechanisms and clinical applications of gut microbiota-derived bioactive compounds in metabolic dysfunction-associated fatty liver disease Chengyun Ma, Jing Wang, Xuanli Song, Xue Wang, Shuai Zong Frontiers in Immunology.2025;[Epub] CrossRef
Reply to correspondence on “Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity” Atsumasa Komori Clinical and Molecular Hepatology.2024; 30(4): 1035. CrossRef
Background/Aims The histological criteria in the 1999 and 2008 scoring systems proposed by the International Autoimmune Hepatitis Group (IAIHG) have their inherent limitations in diagnosing autoimmune hepatitis (AIH). In this study, we evaluated the histology components of four scoring systems (1. revised original scoring system [“1999 IAIHG”], 2. simplified scoring system [“2008 IAIHG”], 3. modified histologic criteria [“2017 UCSF”], and 4. a new histologic criteria proposed by the International AIH Pathology Group [“2022 IAHPG”]) in AIH patients.
Methods Medical records and liver biopsies were retrospectively reviewed for 68 patients from two independent medical institutions, diagnosed with AIH based on the 1999 IAIHG system between 2006 and 2016. The histological features were reviewed in detail, and the four histological scoring systems were compared.
Results Out of the 68 patients, 56 (82.4%) patients met the “probable” or “definite” AIH criteria of the 2008 IAIHG system, and the proportion of histologic score 2 (maximum) was 40/68 (58.8%). By applying the 2017 UCSF criteria, the number of histology score 2 increased to 60/68 (88.2%), and “probable” or “definite” AIH cases increased to 61/68 (89.7%). Finally, applying the 2022 IAHPG histology score resulted in the highest number of cases with histologic score 2 (64/68; 94.1%) and with a diagnosis of “probable” or “definite” AIH (62/68; 91.2%).
Conclusions The recently proposed UCSF/IAHPG histological criteria increased the histology score of AIH. Substituting the histology component of the 2008 IAIHG system with the 2022 IAHPG criteria increased the sensitivity for diagnosing AIH (≥“Probable AIH”) from 82.4% to 91.2%.
Citations
Citations to this article as recorded by
Quo vadis autoimmune hepatitis? - Summary of the 5th international autoimmune hepatitis group research workshop 2024 Bastian Engel, David N. Assis, Mamatha Bhat, Jan Clusmann, Joost PH. Drenth, Alessio Gerussi, María-Carlota Londoño, Ye Htun Oo, Ida Schregel, Marcial Sebode, Richard Taubert JHEP Reports.2025; 7(2): 101265. CrossRef
Histopathology of Autoimmune Hepatitis: An Update Despoina Myoteri, Stratigoula Sakellariou, Dina G. Tiniakos Advances in Anatomic Pathology.2025; 32(6): 414. CrossRef
EASL Clinical Practice Guidelines on the management of autoimmune hepatitis George Dalekos, Nikolaos Gatselis, Joost P. Drenth, Michael Heneghan, Marianne Jørgensen, Ansgar W. Lohse, Maria Londoño, Luigi Muratori, Maria Papp, Marianne Samyn, Dina Tiniakos, Ana Lleo Journal of Hepatology.2025; 83(2): 453. CrossRef
Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis Atsumasa Komori Clinical and Molecular Hepatology.2024; 30(2): 157. CrossRef
Reply to: “Evaluation of the histological scoring systems of autoimmune hepatitis: A significant step towards the optimization of clinical diagnosis” Haeryoung Kim, Sook-Hyang Jeong Clinical and Molecular Hepatology.2024; 30(2): 291. CrossRef
Reply to correspondence on “Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity” Atsumasa Komori Clinical and Molecular Hepatology.2024; 30(4): 1035. CrossRef
The utility of the mHAI scoring system in pediatric autoimmune hepatitis diagnosis and its association with treatment response Wei Chen, Gillian Noel, Mansi Amin, Fengming Chen Annals of Diagnostic Pathology.2024; 73: 152381. CrossRef
Diagnosis and Treatment of Patients with Autoimmune Hepatitis (Experts’ Agreement) Yu. G. Sandler, E. V. Vinnitskaya, K. L. Raikhelson, K. V. Ivashkin, S. N. Batskikh, E. N. Aleksandrova, D. T. Abdurakhmanov, D. I. Abdulganieva, I. G. Bakulin, A. O. Bueverov, S. L. Vorobyev, O. A. Gerasimova, A. I. Dolgushina, M. S. Zhuravleva, L. Yu. I Russian Journal of Gastroenterology, Hepatology, Coloproctology.2024; 34(6): 100. CrossRef
Non-alcoholic fatty liver disease (NAFLD) is a spectrum of diseases characterized by fatty accumulation in hepatocytes, ranging from steatosis, non-alcoholic steatohepatitis, to cirrhosis. While histopathological evaluation of liver biopsies plays a central role in the diagnosis of NAFLD, limitations such as the problem of interobserver variability still exist and active research is underway to improve the diagnostic utility of liver biopsies. In this article, we provide a comprehensive overview of the histopathological features of NAFLD, the current grading and staging systems, and discuss the present and future roles of liver biopsies in the diagnosis and prognostication of NAFLD.
Citations
Citations to this article as recorded by
An electroneutral fluorescent probe for visualization of lipid droplets polarity heterogeneity and NAFLD detection Zhengshuai Wu, Fei Gao, Shuyu Wang, Mengqi Yan, Shuxian Cao, Junjun Liu, Xinyue Li, Guoxia Liu, Sumei Lu, Xuechen Li Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy.2026; 346: 126842. CrossRef
Liver Cancer Risk Across Metabolic Dysfunction-Associated Steatotic Liver Disease and/or Alcohol: A Nationwide Study Byungyoon Yun, Heejoo Park, Sang Hoon Ahn, Juyeon Oh, Beom Kyung Kim, Jin-Ha Yoon American Journal of Gastroenterology.2025; 120(2): 410. CrossRef
Female C57BL/6 mice exhibit protection against nonalcoholic fatty liver disease and diabesity accompanied by differential regulation of hepatic lipocalin prostaglandin D2 synthase Md Asrarul Islam, Rhema Khairnar, Joshua Fleishman, Sandra E. Reznik, Louis Ragolia, Shruthi Gobbooru, Sunil Kumar Molecular and Cellular Endocrinology.2025; 595: 112404. CrossRef
Extracellular vesicle-mediated approaches for the diagnosis and therapy of MASLD: current advances and future prospective Swasthika Gurjar, Ramanarayana Bhat A, Raghavendra Upadhya, Revathi P. Shenoy Lipids in Health and Disease.2025;[Epub] CrossRef
Do Child–Turcotte–Pugh and nutritional assessments predict survival in cirrhosis: A longitudinal study Randhall B Carteri, Claudio A Marroni, Luis F Ferreira, Letícia P Pinto, Juliana Czermainski, Cristiane V Tovo, Sabrina A Fernandes World Journal of Hepatology.2025;[Epub] CrossRef
Unraveling the molecular mechanisms of Fufangduzhong formula in alleviating high-fat diet-induced non-alcoholic fatty liver disease in mice Yu Mou, Yao Tang, Xiuyan Zheng, Xiang Liu, Xuemei Wu, Hongji Wang, Jie Zeng, Qing Rao, Yaacov Ben-David, Yanmei Li, Lei Huang Frontiers in Pharmacology.2025;[Epub] CrossRef
Elevated red blood cell folate levels are associated with metabolic dysfunction-associated steatotic liver disease: results from NHANES 2017–2020 Xin Liao, Song Yu, Lin Wang, Ruyue Zhang, Ke Yu Frontiers in Physiology.2025;[Epub] CrossRef
Investigating the Effects of Gossypetin on Liver Health in Diet-Induced Pre-Diabetic Male Sprague Dawley Rats Karishma Naidoo, Andile Khathi Molecules.2025; 30(8): 1834. CrossRef
Prospective Comparison of 2D-Shear Wave Elastography and Vibration-Controlled Transient Elastography in Assessing Liver Fibrosis in Metabolic Dysfunction-Associated Steatotic Liver Disease Qingxin Li, Yanhang Gao, Dongxuan Wang, Xiaoxue Zhu, Jing Jia, Lili Liu, Huining Tian, Lishuang Wang, Yingwen Zhang, Dezhi Zhang Academic Radiology.2025; 32(9): 5100. CrossRef
Alisol B alleviates MASLD by activating liver autophagy and fatty acid oxidation via Ces2a Congcong Zhang, Lin Chen, Yuwei Jiang, Jiannan Qiu, Yiyou Lin, Guilin Ren, Fangying Xu, Jiale Xi, Zhiling Yu, Xianglu Rong, Xiaobing Dou International Immunopharmacology.2025; 157: 114768. CrossRef
Multiple machine learning algorithms identify 13 types of cell death-critical genes in large and multiple non-alcoholic steatohepatitis cohorts Renao Jiang, Longfei Dai, Xinjian Xu, Zhen Zhang Lipids in Health and Disease.2025;[Epub] CrossRef
Therapeutic potential of Glycyrrhiza glabra L. extract and atorvastatin in HFD-induced MAFLD: in vitro and in vivo exploration Saumya Rastogi, Vishwajeet Bachhar, Vibha Joshi, Sanjay Kumar, Dharamveer Panjwani, Lakhveer Singh, Rajesh Haldhar 3 Biotech.2025;[Epub] CrossRef
A new diphenylmethanone from
Rumex crispus
L. ameliorates sodium palmitate-oleate induced steatosis in HepG2 cells
Wen-Yao Zou, Zheng-Hong Guo, Shuai Dou, Ting Xiao, Wu-de Yang Natural Product Research.2025; : 1. CrossRef
Efficacy of interventions with live combined Bacillus subtilis and Enterococcus faecium enteric-coated capsules in metabolic associated fatty liver disease patients: a meta-analysis of randomized controlled trials Yutong Wu, Hao Wu, Hang Yi Frontiers in Pharmacology.2025;[Epub] CrossRef
Deep learning-based method for grading histopathological liver fibrosis in rodent models of metabolic dysfunction-associated steatohepatitis Soo Min Ko, Jae-ik Shin, Yiyu Hong, Hyunji Kim, Insuk Sohn, Ji-Young Lee, Hyo-Jeong Han, Da Som Jeong, Yerin Lee, Woo-Chan Son Frontiers in Medicine.2025;[Epub] CrossRef
КЛІНІКО-МОРФОЛОГІЧНІ АСПЕКТИ ПЕРВИННОГО НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТУ ЗА НАЯВНОСТІ КОМОРБІДНОЇ ПАТОЛОГІЇ ЖОВЧНОГО МІХУРА О. Ю. Фофанова, В. В. Феденько, З. Я. Гурик, Е. О. Кіндратів, І. Г. Лаб'як Art of Medicine.2025; : 113. CrossRef
Calycosin-7-O-β-D-glucoside alleviates nonalcoholic fatty liver disease by regulating short-chain fatty acids metabolism and metabolic regulators Yanping Zeng, Xinrun Huang, Yuci Ma, Xiaodie Di, Zhao Li, Hebin Wang, Xiaodong Wei The Journal of Nutritional Biochemistry.2025; 145: 110018. CrossRef
Assessing Nonalcoholic Fatty Liver Disease in Type 2 Diabetes Patients at a Tertiary Hospital, Addis Ababa, Ethiopia Edomias Adyamseged Berhe, Rediet Ambachew Sema, Yididya Mehari Tesfaye, Abel Andargie Berhane, Mikale Dawit, Ephrem Mamo Gebrehiwot, Subah Abderehim Yesuf, Balamurugan Ramatchandirin Journal of Diabetes Research.2025;[Epub] CrossRef
Automated Detection of Non‐Alcoholic Fatty Liver Disease Using Histopathological Images: A Systematic Review Hamed Zamanian, Ahmad Shalbaf, Maryam Parvizi, Roohallah Alizadehsani, Ru‐San Tan, U. Rajendra Acharya WIREs Data Mining and Knowledge Discovery.2025;[Epub] CrossRef
Polarity Prompting Vision Foundation Models for Pathology Image Analysis Chong Yin, Siqi Liu, Kaiyang Zhou, Vincent Wai-Sun Wong, Pong C. Yuen IEEE Transactions on Medical Imaging.2025; 44(11): 4579. CrossRef
Clinical Profile of Psoriasis Patients With Comorbid Fatty Liver and Risk Factors for Advanced Liver Fibrosis in Those With Metabolic Dysfunction–Associated Steatotic Liver Disease Hidenori Watabe, Tomomitsu Miyagaki, Kaori Nakajima, Ken Go, Tatsuro Okano, Takafumi Kadono The Journal of Dermatology.2025;[Epub] CrossRef
Matcha mitigates metabolic and inflammatory disturbances induced by high-fat-sucrose diets in rats Nourhan M. Abd El-Aziz, Marwa R. Elbakatoshy, Ebtehal A. Farrage, Oscar Zannou, Reza Tahergorabi, Ayman M. Khalifah, Majid Aminzare, Mohamed G. Shehata Journal of Functional Foods.2025; 135: 107112. CrossRef
Metabolic Dysfunction-Associated Steatohepatitis in Focus: Pathogenesis, Non-Invasive Diagnostics, and Future Approaches Abdulrahman Ismaiel, Mhd Bashir Almonajjed, Cristina Sorina Catana, Stefan-Lucian Popa, Dan L. Dumitrascu Archives of Medical Research.2025; 56(8): 103350. CrossRef
Association of Stroke With Metabolic Dysfunction–Associated Fatty Liver Disease With and Without CKD Yuhao Li, Shouling Wu, Jingli Gao, Yijun Zhang, Yingting Zuo, Xue Tian, Shuohua Chen, Aijun Xing, Anxin Wang, Yan He American Journal of Kidney Diseases.2024; 83(4): 477. CrossRef
Sex-specific differences in ectopic fat and metabolic characteristics of paediatric nonalcoholic fatty liver disease Eun Hye Lee, Ji Young Kim, Hye Ran Yang International Journal of Obesity.2024; 48(4): 486. CrossRef
Research progress, challenges and perspectives of phospholipids metabolism in the LXR‑LPCAT3 signaling pathway and its relation to NAFLD (Review) Junmin Wang, Jiacheng Li, Yugang Fu, Yingying Zhu, Liubing Lin, Yong Li International Journal of Molecular Medicine.2024;[Epub] CrossRef
Proposal of a Novel Serological Algorithm Combining FIB-4 and Serum M2BPGi for Advanced Fibrosis in Nonalcoholic Fatty Liver Disease Sang Yi Moon, Yang Hyun Baek, Se Young Jang, Dae Won Jun, Ki Tae Yoon, Young Youn Cho, Hoon Gil Jo, Ae Jeong Jo Gut and Liver.2024; 18(2): 283. CrossRef
Lipid droplet detection in histopathological images using reinforcement learning Yoshitomi Harada, Haruto Nishida, Keiko Matsuura Biotechnology & Biotechnological Equipment.2024;[Epub] CrossRef
Evaluating the relative importance of different blood pressure indices in screening for NAFLD: a survey report based on a health examination population Chong Hu, Ziqi Yu, Changli Wei, Guotai Sheng, Jianyong Chen, Yang Zou Frontiers in Cardiovascular Medicine.2024;[Epub] CrossRef
Perilipins: A family of five fat‐droplet storing proteins that play a significant role in fat homeostasis Preethi Chandrasekaran, Sabine Weiskirchen, Ralf Weiskirchen Journal of Cellular Biochemistry.2024;[Epub] CrossRef
A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice Rose A. Willett, Volodymyr P. Tryndyak, Jennifer M. Hughes Hanks, Lana Elkins, Suresh K. Nagumalli, Mark I. Avigan, Sharon A. Ross, Gonçalo Gamboa da Costa, Frederick A. Beland, Ivan Rusyn, Igor P. Pogribny Toxicology and Applied Pharmacology.2024; 491: 117046. CrossRef
A peptide alleviated oxidative damages in the L02 cells and mice liver Gan Gao, Zhiyang Zhang, Qiheng Wang, Zhihui Xie, Bing Liu, Hongliang Huang Biochemical and Biophysical Research Communications.2024; 734: 150643. CrossRef
Targeting long non-coding RNA H19 as a therapeutic strategy for liver disease Yulan Shi, Fenghua Qu, Shiyun Zeng, Xinchen Wang, Yuting Liu, Qirui Zhang, Ding Yuan, Chengfu Yuan Progress in Biophysics and Molecular Biology.2024; 194: 1. CrossRef
Transcription factor ETV4 plays a critical role in the development of non-alcoholic fatty liver disease Bhavani Gadiraju, Jhansi Magisetty, Vijay Kondreddy International Journal of Biological Macromolecules.2024; 282: 137235. CrossRef
Arctium lappa L. Extract Alleviates Non-Alcoholic Fatty Liver Injury in Mices 娜 李 Hans Journal of Medicinal Chemistry.2024; 12(04): 309. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in Type 2 Diabetes Mellitus: A Review and Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association Jaehyun Bae, Eugene Han, Hye Won Lee, Cheol-Young Park, Choon Hee Chung, Dae Ho Lee, Eun-Hee Cho, Eun-Jung Rhee, Ji Hee Yu, Ji Hyun Park, Ji-Cheol Bae, Jung Hwan Park, Kyung Mook Choi, Kyung-Soo Kim, Mi Hae Seo, Minyoung Lee, Nan-Hee Kim, So Hun Kim, Won- Diabetes & Metabolism Journal.2024; 48(6): 1015. CrossRef
Evaluation of autoimmune phenomena in patients with nonalcoholic fatty liver disease on the basis of liver pathology Yu-Jin Zhu, Yan Zhang, Yao Rao, Yong Jiang, Yong-Gang Liu, Jian-Zhou Li, Jia-Qi Yuan, Ying Zhao, Wen-Wen Zheng, Lin Ma, Chun-Yan Wang, Jia Li World Journal of Hepatology.2024; 16(12): 1407. CrossRef
Gut microbiome and nonalcoholic fatty liver disease Meng-Yuan Wu, Jian-Gao Fan Hepatobiliary & Pancreatic Diseases International.2023; 22(5): 444. CrossRef
Background/Aims The core needle biopsy (CNB), fine needle aspiration cytology (FNAC) and touch imprint cytology (TIC) are commonly used tools for the diagnosis of hepatic malignancies. However, little is known about the benefits and criteria for selecting appropriate technique among them in clinical practice. We aimed to compare the sensitivity of ultrasound-guided CNB, FNAC, TIC as well as combinations for the diagnosis of hepatic malignancies, and to determine the factors associated with better sensitivity in each technique.
Methods From January 2018 to December 2019, a total of 634 consecutive patients who received ultrasound-guided liver biopsies at the National Taiwan University Hospital was collected, of whom 235 with confirmed malignant hepatic lesions receiving CNB, FNAC and TIC simultaneously were enrolled for analysis. The clinical and procedural data were compared.
Results The sensitivity of CNB, FNAC and TIC for the diagnosis of malignant hepatic lesions were 93.6%, 71.9%, and 85.1%, respectively. Add-on use of FNAC or TIC to CNB provided additional sensitivity of 2.1% and 0.4%, respectively. FNAC exhibited a significantly higher diagnostic rate in the metastatic cancers (P=0.011), hyperechoic lesions on ultrasound (P=0.028), and those with depth less than 4.5 cm from the site of needle insertion (P=0.036).
Conclusions The sensitivity of CNB is superior to that of FNAC and TIC for the diagnosis of hepatic malignancies. Nevertheless, for shallow (depth <4.5 cm) and hyperechoic lesions not typical for primary liver cancers, FNAC alone provides excellent sensitivity.
Citations
Citations to this article as recorded by
Role of imaging-guided biopsy for hepatocellular carcinoma Roberto Cannella, Zachary T. Berman, Nikhil V. Tirukkovalur, Samer T. Tohme, Marta I. Minervini, Alessandro Furlan European Journal of Radiology.2025; 191: 112271. CrossRef
Novel and less invasive biomarker assays to measure liver ATP7B in Wilson disease patients Rosanna J. Jiang, Lucy Chen, Kimberly Amburgey, Danie P. M. La, Brodie Fischbacher, Erle M. Holgersen, Lucienne Ronco, Adam J. Gehring, Jordan J. Feld, Kahlin Cheung-Ong Scientific Reports.2025;[Epub] CrossRef
Combined fine needle aspiration cytology and core needle biopsy in the same setting: A two‐years’ experience Valeria Ciliberti, Elisabetta Maffei, Angela D'Ardia, Francesco Sabbatino, Bianca Serio, Antonio D'Antonio, Pio Zeppa, Alessandro Caputo Cytopathology.2024; 35(1): 78. CrossRef
Patient‐Derived Organoids as Therapy Screening Platforms in Cancer Patients Danial Khorsandi, Jia‐Wei Yang, Samuel Foster, Safoora Khosravi, Negar Hosseinzadeh Kouchehbaghi, Fahimeh Zarei, Yun Bin Lee, Farhana Runa, Ankit Gangrade, Leon Voskanian, Darbaz Adnan, Yangzhi Zhu, Zhaohui Wang, Vadim Jucaud, Mehmet Remzi Dokmeci, Xiling Advanced Healthcare Materials.2024;[Epub] CrossRef
Risk factors of non-diagnostic percutaneous liver tumor biopsy: a single-center retrospective analysis of 938 biopsies based on cause of error Shintaro Kimura, Miyuki Sone, Shunsuke Sugawara, Chihiro Itou, Takumi Oshima, Mizuki Ozawa, Rakuhei Nakama, Sho Murakami, Yoshiyuki Matsui, Yasuaki Arai, Masahiko Kusumoto Japanese Journal of Radiology.2024;[Epub] CrossRef
Usefulness of on‐site cytology of liver tumor biopsy in specimen sampling for cancer genomic profiling test Tasuku Nakabori, Yutaro Abe, Sena Higashi, Kaori Mukai, Risa Yoshioka, Yuki Morimoto, Yuki Koyanagi, Satoshi Tanada, Shigenori Nagata, Keiichiro Honma, Kazuyoshi Ohkawa Cancer Medicine.2023; 12(7): 7888. CrossRef
Association between Biomarkers (VEGF-R2, VEGF-R3, VCAM-1) and Treatment Duration in Patients with Neuroendocrine Tumors Receiving Therapy with First-Generation Somatostatin Analogues Violetta Rosiek, Ksenia Janas, Beata Kos-Kudła Biomedicines.2023; 11(3): 842. CrossRef
Sensitivity of cytology in liver tumor biopsy and its significance in the prompt clinical diagnosis of non‐hepatocellular carcinoma Tasuku Nakabori, Yutaro Abe, Sena Higashi, Kaori Mukai, Azusa Shingetsu, Sanako Nishimura, Sayoko Tsuzaki, Ayumi Ryu, Satoshi Tanada, Shigenori Nagata, Keiichiro Honma, Kazuyoshi Ohkawa Cancer Medicine.2023; 12(11): 12336. CrossRef
Refining Liver Biopsy in Hepatocellular Carcinoma: An In-Depth Exploration of Shifting Diagnostic and Therapeutic Applications Zeno Spârchez, Rareș Crăciun, Iuliana Nenu, Lavinia Patricia Mocan, Mihaela Spârchez, Tudor Mocan Biomedicines.2023; 11(8): 2324. CrossRef
Reliability of combined fine needle aspiration and core needle biopsies in the diagnosis of liver lesions: An 8‐year institutional experience Yuan Shen, Evgeniya Angelova, Mariana Moreno Prats, Cecilia Clement, Vicki Schnadig, Heather Stevenson‐Lerner, Jing He Cytopathology.2022; 33(4): 472. CrossRef
Image-guided Percutaneous Biopsy of the Liver Ather Adnan, Rahul A. Sheth Techniques in Vascular and Interventional Radiology.2021; 24(4): 100773. CrossRef
Touch Imprint Intraoperative Flow Cytometry as a Complementary Tool for Detailed Assessment of Resection Margins and Tumor Biology in Liver Surgery for Primary and Metastatic Liver Neoplasms Georgios Markopoulos, Georgios Glantzounis, Anna Goussia, Georgios Lianos, Anastasia Karampa, George Alexiou, George Vartholomatos Methods and Protocols.2021; 4(3): 66. CrossRef
Biopsy or cytology for diagnosing hepatic focal lesions? Haeryoung Kim Clinical and Molecular Hepatology.2021; 27(2): 278. CrossRef
First
Prev
